New pulmonary hypertension guideline challenges use of common ...( A new evidence-based guideline for pulm...)

A new evidence-based guideline for pulmonary arterial hypertension (PAH) cautions the use of calcium channel blockers, a commonly used treatment for high blood pressure, in unstable patients due to the potentially fatal side effects associated with the medication. PAH is a life-threatening condition that occurs when the arteries that supply blood to the lungs become constricted, limiting the blood flow to the lungs and, ultimately, causing high blood pressure to develop within the lung arteries.

The American College of Chest Physicians (ACCP) Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guideline provides recommendations for diagnosing and treating PAH. Published in the July issue of CHEST, the peer-reviewed journal of the ACCP, the guideline was developed by a multidisciplinary panel of experts from five medical specialties and is endorsed by the American College of Cardiology Foundation, American College of Rheumatology, American Heart Association, and the Pulmonary Hypertension Association. Panel members recommend against the empiric use of calcium channel blockers or their use in patients who do not respond to acute pulmonary vasodilator testing, citing an increased risk of adverse and potentially fatal events related to the use of the medication. Due to the severity of the disease, the panel also advises genetic testing for patients with a family history of PAH and advance screening for patients with certain chronic diseases who are predisposed to PAH.

"Calcium channel blockers are regularly used to treat high blood pressure because they limit calcium entry into the cells and dilate the constricted systemic blood vessels, thereby lowering blood pressure. This rationale is frequently applied to their use in PAH; however, when they are used in patients with PAH whose narrowed pulmonary arteries are not caused by dynamic vessel constriction, the side effects can be fatal," said Panel Cha
'"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
12-Jul-2004

Page: 1 2 3
Related biology news :

1. Genes appear to play a role in development of chronic obstructive pulmonary disease
2. Vanderbilt doctors use Viagra to treat infants with pulmonary hyptertension
3. Nuclear medicine aids early diagnosis of pulmonary anthrax
4. Genetic defect in sporadic cases of the lung disorder pulmonary hypertension
5. Hopkins wins $14 million NIH grant for genetic cardiopulmonary disease research
6. Two NHLBI studies confirm finding of gene in primary pulmonary hypertension
7. Statement from Dr. Claude Lenfant on discovery of the gene for primary pulmonary hypertension
8. Gene discovered for primary pulmonary hypertension
9. Vioxx in high doses causes hypertension
10. Sex-specific differences in gene expression related to drug metabolism and hypertension
11. Obesity and hypertension: Two epidemics or one?